Table 1 (Abstract P040) Effectiveness (missing data omitted)
From: Abstracts from the 17th European Headache Congress (EHC)
≥ 50% MMD reduction over 6 months (N=826) | 444 (53.8%) | |
EM (N=474) | 277 (58.4%) | |
CM (N=352) | 167 (47.4%) | |
MMD | Baseline (N=926) | 12.6 |
Month 6 (N=712) | 5.3 | |
Month 12 (N=484) | 5.0 | |
MIDAS | Baseline (N=545) | 75.2 |
Month 6 (N=500) | 32.0 | |
Month 12 (N=296) | 27.3 | |
HIT-6 | Baseline (N=581) | 65.9 |
Month 6 (N=510) | 57.2 | |
Month 12 (N=303) | 57.0 | |
Acute medication use (days) | Baseline (N=901) | 9.6 |
Month 6 (N=712) | 3.7 | |
Month 12 (N=484) | 3.7 | |